Health withdraws a drug against fungal infection due to manufacturer failures

Health withdraws all units from these batches due to non-compliance with correct manufacturing standards. These are batches 012048D, with an expiration date of December 31, 2022. Caspofingina SUN belongs to the group of drugs called antifungals, used for infections in children, adolescents and adults. Health has withdrawn from the market a drug against fungal infection due to manufacturer faults. The Spanish Agency for Medicines and Health Products (AEMPS) has ordered the withdrawal of two batches of Caspofungina SUN powder for infusion (an antifungal used to combat fungal invasions) due to manufacturing failures. This is indicated by the AEMPS, which details that the batches withdrawn have been manufactured by Mefar LLac Sanayii AS (Turkey) and marketed in Spain by SUN Pharma Laboratories SL, based in Catalonia. Failure to comply with manufacturing standards Specifically, it is batch 012048D, with an expiration date of 31 December December 2022, and 101002C which expires on January 31, 2023. Health details that the order to withdraw all units from these batches from the market for their return to the laboratory is due to “non-compliance with the manufacturer’s correct manufacturing standards” .According to the manufacturer, Caspofingina SUN belongs to a group of medicines called antifungals, used for infections in children, adolescents and adults.